Want to join the conversation?
$AMGN and Brussels-based biopharma company UCB announced the submission of a Biologics License Application (BLA) to the US FDA for romosozumab, an investigational antibody for treating osteoporosis in postmenopausal women at increased risk of fracture. The BLA is based on data from Phase 3 placebo-controlled FRAME study in about 7,200 patients.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.